C1 inhibitor: molecular and clinical aspects

Area of Science:

• Biochemistry
• Immunology
• Molecular Biology

Background:

• C1 inhibitor (C1-INH) is a serine protease inhibitor regulating complement, coagulation, and inflammatory systems.
• C1-INH's dual function involves protease inhibition via its serpin domain and inflammatory modulation via its nonserpin domain.
• Heterozygous C1-INH deficiency leads to hereditary angioedema (HAE), characterized by recurrent swelling episodes.

Purpose of the Study:

• To review the multifaceted roles of C1 inhibitor in physiological and pathological conditions.
• To discuss the therapeutic potential of C1-INH, including its use in hereditary angioedema.
• To highlight the development and ongoing clinical trials of recombinant C1-INH.

Main Methods:

• Literature review of C1-INH's biochemical properties and clinical implications.
• Analysis of C1-INH's involvement in hereditary angioedema and other inflammatory diseases.
• Examination of therapeutic strategies utilizing C1-INH, including plasma-derived and recombinant forms.

Main Results:

• C1-INH's inhibition of proteases and modulation of inflammation are crucial for maintaining homeostasis.
• C1-INH deficiency is the direct cause of hereditary angioedema, manifesting as vascular permeability increases.
• Recombinant C1-INH is a promising therapeutic agent for HAE, with clinical trials underway.

Conclusions:

• C1-INH is a vital regulator with significant therapeutic implications, particularly in HAE.
• Further research and clinical trials are essential to fully exploit C1-INH's therapeutic potential.
• The development of recombinant C1-INH offers a new avenue for HAE treatment, potentially renewing interest in C1-INH-based therapies.